Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Liver Cirrhosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    536 result(s) found for: Liver Cirrhosis. Displaying page 4 of 27.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-000554-31 Sponsor Protocol Number: CNTO1275PBC2001 Start Date*: 2011-09-21
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Ustekinumab in Subjects with Primary Biliary Cirrhosis Who had an I...
    Medical condition: Primary Biliary Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004871 10036680 Primary biliary cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005969-13 Sponsor Protocol Number: AXA1665-101 Start Date*: 2021-08-11
    Sponsor Name:Axcella Health, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AXA1665 in Subjects With Liver Cirrhosis and Prior Overt Hepatic Encephalopathy (EM...
    Medical condition: Overt Hepatic Encephalopathy in Subjects with Liver Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10019660 Hepatic encephalopathy PT
    20.0 100000004871 10024667 Liver cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) PL (Completed) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-001132-19 Sponsor Protocol Number: 1-10-72-67-17 Start Date*: 2017-07-04
    Sponsor Name:Aarhus University Hospital
    Full Title: Effects of Metformin on portal hypertension in patients with cirrhosis.
    Medical condition: cirrhosis and portal hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10036201 Portal hypertensions HLT
    20.0 100000004871 10009211 Cirrhosis liver LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-004442-15 Sponsor Protocol Number: HISTORY Start Date*: 2013-09-11
    Sponsor Name:University Leipzig
    Full Title: High-dose intravenous silibinin infusions during 10 days as add-on treatment to triple therapy (telaprevir, peginterferon alpha and ribavirin) in cirrhotic GT 1 hepatitis C virus infected patients ...
    Medical condition: High-dose intravenous silibinin infusions during 10 days as add-on treatment to triple therapy (telaprevir, peginterferon alpha and ribavirin) in cirrhotic GT 1 hepatitis C virus infected patients ...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004871 10019642 Hepatic cirrhosis NOS LLT
    16.1 100000004848 10072848 Hepatitis C virus genotype 1 positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003932-22 Sponsor Protocol Number: IM025-017 Start Date*: 2022-10-04
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults with Compensated Cirrhosis from Nonalcoholic ...
    Medical condition: Compensated Cirrhosis from Nonalcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10019669 Hepatic fibrosis and cirrhosis HLT
    20.1 100000004871 10064844 Compensated cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) DE (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-001424-12 Sponsor Protocol Number: 747-201 Start Date*: 2009-04-21
    Sponsor Name:Intercept Pharmaceuticals
    Full Title: A Study of INT-747 (6-ECDCA) Monotherapy in Patients with Primary Biliary Cirrhosis
    Medical condition: Primary biliary cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10019805 - Hepatobiliary disorders 10004661 Biliary cirrhosis primary PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) ES (Completed) AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001661-15 Sponsor Protocol Number: 087-CL-089 Start Date*: 2007-10-11
    Sponsor Name:Astellas Pharma US, Inc
    Full Title: A Phase 2, Randomized, Double Blind, Placebo Controlled, Dose Escalation Study to Assess the Safety and Effects of Intravenous Conivaptan on the Hepatic Hemodynamic Response in Stable Euvolemic or ...
    Medical condition: stable euvolemic or hypervolemic cirrhotic patients with serum sodium 115 – 140 mEq/L Pacientes cirróticos euvolémicos o hipervolémicos estables con un valor de sodio sérico comprendido entre 115 ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019641 Hepatic cirrhosis PT
    9.1 10021038 Hyponatremia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-000102-35 Sponsor Protocol Number: 35128 Start Date*: 2014-12-19
    Sponsor Name:Clinica Medica 5
    Full Title: Effect of administration "add on" of Rifaximin on portal hypertension of patients with liver cirrhosis and esophageal varices in standard therapy with propranolol
    Medical condition: Portal hypertension, liver cirrhosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001711-31 Sponsor Protocol Number: M0002-BEL-C201 Start Date*: 2007-05-23
    Sponsor Name:Movetis NV
    Full Title: A randomized, double blind, placebo controlled, phase II, dose-titration trial to explore the safety, tolerability, pharmacokinetic profile and efficacy of M0002 in cirrhotic subjects with ascites ...
    Medical condition: Cirrhotic subjects with ascites and hyponatremia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009213 Cirrhosis of liver LLT
    9.1 10003445 Ascites LLT
    9.1 10021038 Hyponatremia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001425-10 Sponsor Protocol Number: 747-202 Start Date*: 2008-10-13
    Sponsor Name:Intercept Pharmaceuticals
    Full Title: A Study of INT-747 (6-ECDCA) in Combination with Ursodeoxycholic Acid (URSO®, UDCA) in Patients with Primary Biliary Cirrhosis
    Medical condition: Primary biliary cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004661 Biliary cirrhosis primary PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) FR (Completed) AT (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001626-26 Sponsor Protocol Number: INCA Start Date*: 2015-01-26
    Sponsor Name:Saarland University
    Full Title: Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver cirrhosis and ascites (INCA trial)
    Medical condition: Liver cirrhosis and ascites
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10024667 Liver cirrhosis LLT
    20.0 10017947 - Gastrointestinal disorders 10003445 Ascites PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002628-96 Sponsor Protocol Number: R-RID Start Date*: 2016-09-21
    Sponsor Name:Imperial College London
    Full Title: A multi-centre, double-blind, randomised, controlled clinical trial of Rifaximin to reduce infection in patients admitted to hospital with decompensated cirrhosis
    Medical condition: Decompensated cirrhosis - liver disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-003238-32 Sponsor Protocol Number: v1 Start Date*: 2004-12-13
    Sponsor Name:Dept. of Clinical Pharmacology
    Full Title: Effect of pioglitazone on portal and systemic hemodynamics in patients with advanced cirrhosis
    Medical condition: Cirrhosis of the liver
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001524-31 Sponsor Protocol Number: URT-15/PBC Start Date*: 2008-08-26
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, double-dummy, randomized, crossover, multicentre phase IV clinical study comparing the effect of Ursofalk® 500 mg tablets od versus Ursofalk® 250 mg capsules od on liver enzyme parame...
    Medical condition: Treatment of primary biliary cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036680 Primary biliary cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001789-28 Sponsor Protocol Number: IG1601 Start Date*: 2018-04-25
    Sponsor Name:Instituto Grifols S.A.
    Full Title: Prevention of Mortality with Long-Term Administration of Human Albumin in Subjects with Decompensated Cirrhosis and Ascites
    Medical condition: Subjects with decompensated cirrhosis and ascites
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10064704 Decompensated cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) FR (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) IT (Completed) HU (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-005198-29 Sponsor Protocol Number: CB8025-31731-RE Start Date*: 2021-05-10
    Sponsor Name:CymaBay Therapeutics, Inc.
    Full Title: ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)
    Medical condition: Primary Biliary Cholangitis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004871 10036680 Primary biliary cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) CZ (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-006742-34 Sponsor Protocol Number: ezetimibe27 Start Date*: 2007-12-20
    Sponsor Name:Barts and The London NHS Trust
    Full Title: The effect of Ezetimibe or pyridoxine in Patients with Primary Biliary Cirrhosis.
    Medical condition: primary biliary cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036680 Primary biliary cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002677-19 Sponsor Protocol Number: IG1605 Start Date*: 2019-07-24
    Sponsor Name:Instituto Grifols S.A.
    Full Title: Pathogenesis of Acute on Chronic Liver Failure (ACLF) and Mechanisms of Action of Plasma Exchange with Human Serum Albumin 5% (PE-A 5%) in Decompensated Cirrhotic Subjects with Systemic Inflammatio...
    Medical condition: Group 1 and 2: Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected either at admission or during hospitalization Group 3: Subject with cirrhosis hospitalized for Acute decompensat...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004871 10064704 Decompensated cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DE (Prematurely Ended) FR (Completed) AT (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000145-12 Sponsor Protocol Number: 5997 Start Date*: 2012-08-15
    Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Rituximab for the Treatment of Fatigue in Primary Biliary Cirrhosis (PBC)
    Medical condition: Severe fatigue in Primary Biliary Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10019805 - Hepatobiliary disorders 10004661 Biliary cirrhosis primary PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023366-49 Sponsor Protocol Number: Bosentan for HPS Start Date*: 2011-07-22
    Sponsor Name:Med. Univ. Wien, Univ. Klinikum für Interne Medizin III
    Full Title: Bosentan for treatment ofhepatopulmonary syndrome in patients with liver cirrhosis - a prospective double blind randomized controlled clinical study
    Medical condition: HPS is by far the most frequent respiratory complication of cirrhosis leading to significantly increased mortality. The only therapeutic option is liver transplantation. Many patients with HPS who ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 25 03:50:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA